MedTrace Logo

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

NCT05411757 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-06-09

No results posted yet for this study

Summary

This is an open-label, nonrandomized investigator-initiated clinical trial to evaluate the safety, tolerability, and efficacy of IBR900 cell injection in combination with Lenvatinib or bevacizumab in subjects with advanced primary liver cancer.

Conditions

  • Advanced Primary Liver Cancer

Interventions

COMBINATION_PRODUCT

IBR900 combined with Lenvatinib

IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight \< 60kg, 8mg/qd; administered continuously from D5 of the first cycle

COMBINATION_PRODUCT

IBR900 combined with Bevacizumab

IBR900 cell injection: 4.0×10\^9 cells, D1,D3 of each cycle. Bevacizumab:15mg/kg, D1 of each cycle.

Sponsors & Collaborators

  • Imbioray (Hangzhou) Biomedicine Co., Ltd.

    collaborator INDUSTRY

  • Shandong Public Health Clinical Center

    lead OTHER_GOV

Principal Investigators

  • Jingbo Wang · Head of the department of Biology and Cell therapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-06-30
Completion
2023-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05411757 on ClinicalTrials.gov